Modified Amniotic Fluid Compositions for Wound Healing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for skin diseases and pulmonary disorders are often ineffective in promoting rapid healing and reducing scarring, and existing methods for wound care are limited in enhancing tissue regeneration and minimizing scar formation.
Innovation Solution
The use of modified amniotic fluid, which is sterilized and desalted, and combined with a pharmaceutically acceptable carrier, administered through devices like dual-chamber sprayers or double syringes to treat skin diseases, pulmonary disorders, and wounds, promoting healing and reducing scar formation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional treatments are used for skin diseases and pulmonary disorders, then standard care is provided, but healing is slow and scarring occurs
Solution Approach 1:
The patent applies parameter changes by modifying amniotic fluid through sterilization and desalting processes, transforming it from a natural biological fluid into a therapeutic composition with controlled properties. This processed amniotic fluid contains growth factors and cytokines that accelerate tissue regeneration and reduce scarring, directly addressing the healing rate and scar formation contradiction
Solution Approach 2:
The patent uses amniotic fluid as an intermediary substance that mediates between the injury and the healing process. The fluid delivers bioactive molecules (growth factors, cytokines) to the wound site, facilitating tissue regeneration and minimizing scar formation without directly interfering with the natural healing cascade
2Reliability
If amniotic fluid is used topically, then wound healing is enhanced, but the fluid requires modification for therapeutic use
Solution Approach 1:
The patent extracts and removes unwanted components from amniotic fluid through sterilization and desalting processes. This extraction of harmful or interfering elements (bacteria, salts, cellular debris) while retaining beneficial growth factors creates a reliable therapeutic product that is easier to manufacture and apply consistently
Solution Approach 2:
The patent performs preliminary modification of amniotic fluid (sterilization, desalting, concentration) before clinical application. This preliminary processing ensures the fluid is ready for immediate use with consistent therapeutic properties, reducing variability and improving reliability while establishing a standardized manufacturing process
Data Source
AI summary
The present disclosure provides compositions composed of amniotic fluid and/or modified amniotic fluid, a pharmaceutically acceptable carrier, and optionally a placental tissue graft, micronized placental tissue components, or extracts derived therefrom. Also described are systems and apparatuses for administering or storing said compositions, as well as methods of treatment using said compositions.